帕罗西汀对终末期肾病透析患者的焦虑抑郁障碍的治疗研究

目的评价帕罗西汀治疗终末期肾病（ERSD）患者的焦虑与抑郁症状的疗效。方法对74名伴发抑郁焦虑障碍终末期肾病患者，进行为期4周的随机对照研究，实验组、对照组各37例，以汉密顿焦虑量表（HAMA）和汉密顿抑郁量表（HAMD）评定疗效。结果帕罗西汀组焦虑与抑郁症状的减轻明显优于对照组（P〈0．05—0．01）。结论帕罗西汀能有效减轻终末期肾病患者的焦虑、抑郁症状，且不良反应小，提高对透析治疗的依从性。

The Therapeutic Effects of Paroxetine for Anxiety and Depression of ERSD

Objective To evaluate the therapeutic effects of paroxetine for anxiety and depression of end-stage-renal disease(ERSD). Methods 74 patients of ERSD with depression and anxiety were divided into 2 groups and entered an 4-week randomized placebo-controlled trial, 37 patients were treated by paroxctine,Hamilton Rating Scale for Depression(HAMD) and Hamilton Rating Scale for Anxiety (HAMA) were used to evaluate the therapeutic effects of paroxetine,and controlled with 37 trial. Results Compared with the scores before therapy, the scores evaluated by HAMD and HAMA of paroxetine groups after therapy decreased signifi-cantly(P<0.05～0.01). Conclusion Paroxetine effectively reduces the severity of depression and anxiety in ERSD patients, this treatment also can produced a trend better